Anzeige
Mehr »
Dienstag, 11.11.2025 - Börsentäglich über 12.000 News
Nuklear-Deal startet: 80-Mrd.-Dollar-Atomoffensive der USA
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
195 Leser
Artikel bewerten:
(1)

Shilpa Medicare Limited: Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices

RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigious Gold Medal by EcoVadis, the world's most trusted provider of business sustainability ratings.

Shilpa Medicare Limited Logo

The company achieved an exceptional score of 82/100, placing it in the 98th percentile globally among 130,000 + companies evaluated by EcoVadis. This performance underscores our industry-leading Environmental, Social and Governance (ESG) practices and reflects our long-term commitment to building a responsible, resilient, and sustainable pharmaceutical enterprise.

EcoVadis assesses organizations on four key pillars - Environment, Labor & Human Rights, Ethics, and Sustainable Procurement - and this recognition positions Shilpa Pharma Lifesciences among the top few global companies rated for sustainable business operations.

Speaking on this milestone, Mr. Keshav Bhutada, ED & CEO of Shilpa Pharma Lifesciences emphasized that "Sustainability and innovation are integral to Shilpa's CDMO growth strategy to work with global innovator companies for their New chemical Entity programs. The EcoVadis Gold Medal is a testimony to our relentless efforts toward responsible manufacturing, ethical governance, and inclusive growth that creates enduring value for patients and partners. We look forward to work with more global innovator companies"

This achievement further strengthens Shilpa's credentials with global customers, investors, and partners, reinforcing their positioning as a trusted global CDMO partner with sustainability at the core of their operations.

About Shilpa Medicare Limited

Shilpa Medicare Limited (BSE: 530549 | NSE: SHILPAMED) is a leading Indian pharmaceutical company focused on the development, manufacture, and marketing of APIs, formulations, and biologics across oncology, infectious diseases, and specialty segments. With expertise in complex generics, novel drug delivery systems, and CDMO services, Shilpa serves patients in over 80 countries. For more information, visit www.vbshilpa.com

Forward-Looking Statement Disclaimer

This document contains forward-looking statements describing the Company's objectives, plans, and expectations for future performance. Actual results may differ materially due to risks and uncertainties including regulatory approvals, clinical outcomes, market conditions, and competitive developments. Shilpa Medicare undertakes no obligation to update forward-looking statements to reflect subsequent events or circumstances.

Logo - https://mma.prnewswire.com/media/2489785/Shilpa_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/shilpa-pharma-lifesciences-awarded-ecovadis-gold-medal-for-outstanding-sustainability-practices-302610563.html

© 2025 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.